Diabetes and psoriasis drugs help Lilly beat forecasts
Eli Lilly (NYSE: LLY) today posted second-quarter 2019 financial, showing that revenue increased less than 1% to $5.64 billion from $5.59 billion driven by 6% volume growth, and beating Wall Street estimates of $5.6 billion, helped by diabetes drugs Trulicity (dulaglutide) and Basaglar (insulin glargine injection).
Lilly’s shares rose 1.2% to $110.01 in pre-market trading this morning.
The US pharma major recorded net income of $1.33 billion, or $1.44 per share, in the quarter, compared with a loss of $259.9 million, or 25 cents per share, when it recorded acquisition-related charges of $1.62 billion. Excluding special items, Lilly earned $1.5 per share. Analysts on average had expected a profit of $1.45 per share, according to IBES data from Refinitiv.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze